Leveraging the power of big data & AI to unlock microbiome precision medicine.

Partner with Us

Big Data. Groundbreaking analysis

At BiomeSense, we believe the gut microbiome is poised to join genomics as a powerful avenue of personalized medicine, with the potential of transforming the lives of millions worldwide.

To accelerate our path to that future, we developed the first AI-enabled technology platform for reliable, longitudinal, and low-cost generation & analysis of microbiome data. Our mission is to partner with leading scientists and companies across the field, providing them with continuous, comprehensive microbiome data and AI-enabled bioinformatics to unlock the microbiome’s full personalized medicine potential.

learn more
Big Data. Groundbreaking Analysis.
Today
01
02
03
Problem:
Limited Data Availability

Today, microbiome datasets are often limited because of the high cost and difficulty of generating & analyzing data.

As a result, we often can't even observe most host-microbiome interactions - much less leverage them for personalized medicine.

Today's tools
Gut microbiome of cancer patient from diagnosis through treatment
BiomeSense Solution:
GutLab Technology

BiomeSense's GutLab technology enables continuous tracking of the patient's gut microbiome throughout the treatment journey.

These samples are sequenced by BiomeSense & matched to clinical data to create a high-resolution map of the microbiome, revealing extensive natural variation and treatment effects.

01 - GutLab Continuous Data Generation
Gut microbiome of cancer patient from diagnosis through treatment
BiomeSense Solution:
MetaBiome AI Platform

MetaBiome transforms & analyzes the data using both well-established and novel time-series analyses, enabling identification of clinically-relevant shifts and other patterns meriting further investigation.

02 - MetaBiome AI-enabled Analysis
Gut microbiome of cancer patient from diagnosis through treatment
BiomeSense Solution:
Novel Biological Insights

By combining high-resolution data & AI, BiomeSense's platform unlocks an entire dimension of previously inaccessible host-microbiome interactions, such as a potentially novel signature suggesting the gut microbiome may be a biomarker for active tumor burden.

Join us
03 - Change Point Identification
Gut microbiome of cancer patient from diagnosis through treatment
Today
Problem:
Limited Data Availability

Today, microbiome datasets are often limited because of the high cost and difficulty of generating & analyzing data.

As a result, we often can't even observe most host-microbiome interactions - much less leverage them for personalized medicine.

Today's tools
Gut microbiome of cancer patient from diagnosis through treatment
01
BiomeSense Solution:
GutLab Technology

BiomeSense's GutLab technology enables continuous tracking of the patient's gut microbiome throughout the treatment journey.

These samples are sequenced by BiomeSense & matched to clinical data to create a high-resolution map of the microbiome, revealing extensive natural variation and treatment effects.

01 - GutLab Continuous Data Generation
Gut microbiome of cancer patient from diagnosis through treatment
02
BiomeSense Solution:
MetaBiome AI Platform

MetaBiome transforms & analyzes the data using both well-established and novel time-series analyses, enabling identification of clinically-relevant shifts and other patterns meriting further investigation.

02 - MetaBiome AI-enabled Analysis
Gut microbiome of cancer patient from diagnosis through treatment
03
BiomeSense Solution:
Novel Biological Insights

By combining high-resolution data & AI, BiomeSense's platform unlocks an entire dimension of previously inaccessible host-microbiome interactions, such as a potentially novel signature suggesting the gut microbiome may be a biomarker for active tumor burden.

03 - Change Point Identification
Gut microbiome of cancer patient from diagnosis through treatment

BiomeSense Platform

Our platform combines novel hardware with AI-enabled bioinformatics to unlock the personalized medicine potential of the gut microbiome.

Our technology

Partner with Us

We’re partnering with leading scientists, institutions, and companies conducting clinical research into the gut microbiome, with a focus on personalized biomarker discovery and novel product development.

By leveraging our technology, our partners receive continuous, comprehensive microbiome data generation and AI-enabled bioinformatics for unprecedented insight into the microbiome’s role in health and disease.

Join us

Exploratory research

Support understanding host-microbiome interactions and developing hypotheses for future research.

Biomarker Discovery

Support identifying and validating novel personalized microbiome biomarkers.

Product development

Help developing novel therapeutics, diagnostics, probiotics, and other products leveraging the microbiome for health.

Exploratory research

Support understanding host-microbiome interactions and developing hypotheses for future research.

Biomarker Discovery

Support identifying and validating novel personalized microbiome biomarkers.

Product development

Help developing novel therapeutics, diagnostics, probiotics, and other products leveraging the microbiome for health.

Our Team

Our leadership team is focused on unlocking the vast potential of the human gut microbiome by building unique technologies
that will disrupt the industry.

Kevin Honaker

Co-Founder & CEO

Dr. Jack Gilbert

Co-Founder

Dylan Nichols

CTO

Yoshiki Vázquez-Baeza

BIOINFORMATICS LEAD

Nikhil Boddu

MECHATRONICS ENGINEER

Madison Tuffield

RESEARCH ASSOCIATE

Dr. Rob Knight

SCIENTIFIC ADVISOR

Dr. Charles Chiu

SCIENTIFIC ADVISOR

Dr. Savas Tay

SCIENTIFIC ADVISOR & COFOUNDER

Omar Khan

Research Associate

David Bushhouse

SCIENTIST

Latest News